Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement
Scope
As issued by the authors
Redifferentiation therapy (mitogen-activated protein kinase (MAPK) inhibitors before high activity 131I) in unresectable or metastatic radioactive iodine refractory follicular cell-derived thyroid cancer: prospective trial and case report results (iodine uptake restoration 33% to 95%; tumour response 11% to 80%), trial design differences, dosimetry, and key questions for future trials
Original publication
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. Published 30 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →